Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 2:2019:4761054.
doi: 10.1155/2019/4761054. eCollection 2019.

Biomarkers for Alzheimer's Disease in Saliva: A Systematic Review

Affiliations

Biomarkers for Alzheimer's Disease in Saliva: A Systematic Review

Helena Sophia Gleerup et al. Dis Markers. .

Abstract

Background: The histopathological changes of Alzheimer's disease (AD) are detectable decades prior to its clinical expression. However, there is a need for an early, inexpensive, noninvasive diagnostic biomarker to detect specific Alzheimer pathology. Recently developed neuroimaging biomarkers show promising results, but these methods are expensive and cause radiation. Furthermore, the analysis of cerebrospinal fluid (CSF) biomarkers requires an invasive lumbar puncture. Saliva is an easily obtained body fluid, and a stable saliva biomarker would therefore be a promising candidate for a future method for diagnosing AD. The purpose of this systematic review was to investigate studies of biomarkers in saliva samples for the diagnosis of AD.

Methods: The included articles were identified through a literature search in PubMed and Google Scholar for all articles until November 1st, 2018, and furthermore, all reference lists of included articles were reviewed by hand. We included articles written in English investigating saliva from patients with AD and a control group.

Results: A total of 65 studies were identified, whereof 16 studies met the inclusion criteria and were included in the systematic review. A plethora of different biomarkers were investigated, and ten out of the sixteen studies showed a statistical significance in biomarkers between patients with AD and healthy, elderly controls, among these biomarkers for specific AD pathology (amyloid beta 1-42 (Aβ42) and tau).

Conclusion: Aβ42 and tau seem to be worthy candidates for future salivary biomarkers for AD, but other biomarkers such as lactoferrin and selected metabolites also have potential. More studies must be carried out with larger sample sizes and a standardization of the sampling and processing method. Factors such as diurnal variation, AD patients' decreased ability of oral self-care, and salivary flowrates must be taken into consideration.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of the literature search and the study selection.

Similar articles

Cited by

References

    1. Martin Prince A. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. Alzheimer's Disease International; 2015.
    1. What is Alzheimer’s | Alzheimer’s Association. November 2018, https://www.alz.org/alzheimers-dementia/what-is-alzheimers.
    1. Simonsen A. H., Herukka S. K., Andreasen N., et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's & Dementia. 2017;13(3):274–284. doi: 10.1016/j.jalz.2016.09.008. - DOI - PubMed
    1. Fiandaca M. S., Kapogiannis D., Mapstone M., et al. Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimer's & Dementia. 2015;11(6):600–607.e1. doi: 10.1016/j.jalz.2014.06.008. - DOI - PMC - PubMed
    1. Cummings J., Lee G., Ritter A., Zhong K. Alzheimer’s disease drug development pipeline: 2018. Alzheimer's & Dementia. 2018;4:195–214. doi: 10.1016/j.trci.2018.03.009. - DOI - PMC - PubMed

Publication types